Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Alexithymia, an impairment of emotional cognitive processing, is a candidate risk factor for carotid artery plaque formation in HIV-infected patients

Authors: F Vadini, F Sozio, E Mazzotta, C Agostinone, T Ursini, A Agostinone, G Placido, LM Manzoli, G Parruti

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Vascular aging is now one major concern in the care of HIV infected patients, as many factors may contribute to its faster progression in comparison with the general population. We investigated several psychological factors including Alexithymia, Type D personality, Mental and Physical Components (MCS and PCS) of Quality of Life (QoL) and Depression in a single Italian HIV cohort, well characterized for traditional cardiovascular (CV) risk factors and intima-media thickness of carotid arteries. …
Literature
1.
Grabe HJ, et al: Alexithymia, hypertension, and subclinical atherosclerosis in the general population. J Psychosom Res. 2010, 68: 139-10.1016/j.jpsychores.2009.07.015.CrossRefPubMed
2.
Temoshok LR, et al: Type C coping and alexithymia are associated independently and differentially with specific immune mechanisms linked to HIV progression. Brain Behav Immun. 2008, 22: 781-10.1016/j.bbi.2008.02.003.CrossRefPubMed
3.
Beresnevaite M: Exploring the benefits of reducing alexithymia in coronary heart disease patients: a preliminary study. Psychother Psychosom. 2000, 69: 117-10.1159/000012378.CrossRefPubMed
Metadata
Title
Alexithymia, an impairment of emotional cognitive processing, is a candidate risk factor for carotid artery plaque formation in HIV-infected patients
Authors
F Vadini
F Sozio
E Mazzotta
C Agostinone
T Ursini
A Agostinone
G Placido
LM Manzoli
G Parruti
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P70

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Poster presentation

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Poster presentation

A minority of tuberculosis cases occurring during HIV care is possibly preventable

Poster presentation

HIV testing in non-traditional settings: feasibility and acceptability in an acute admissions unit

Poster presentation

CCR5 D32 modifies 15-year mortality risk associated with well-established clinical and immunological factors among HIV-infected patients

Oral presentation

O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis

Poster presentation

Low serum phosphate levels are related to increased cardiovascular risk in HIV-1 infected patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits